Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (581-590 of 692) with videos related to

Pageof 70
Sort By:
Cancer Research|July 23, 2003
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapseSusan M Henshall, Daniel E H Afar, Jordan Hiller, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
The Journal of Headache and Pain|January 10, 2014
Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaireTimothy J Steiner, Gopalakrishna Gururaj, Colette Andrée, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Science (New York, N.Y.)|April 11, 2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancerChris Tran, Samedy Ouk, Nicola J Clegg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
The Journal of Urology|March 28, 2023
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer PatientsKelsey E Breen, Heather Symecko, Kelsey Spielman, et al.
Cancer Research|June 15, 2026
Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate CancerNabil A Siddiqui, Li Zhang, Gabriel DeLeon, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
Pageof 70

Showing results (581-590 of 692) with videos related to

Sort By:
Pageof 70
Cancer Research|July 23, 2003
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapseSusan M Henshall, Daniel E H Afar, Jordan Hiller, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
The Journal of Headache and Pain|January 10, 2014
Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaireTimothy J Steiner, Gopalakrishna Gururaj, Colette Andrée, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Science (New York, N.Y.)|April 11, 2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancerChris Tran, Samedy Ouk, Nicola J Clegg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
The Journal of Urology|March 28, 2023
Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer PatientsKelsey E Breen, Heather Symecko, Kelsey Spielman, et al.
Cancer Research|June 15, 2026
Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate CancerNabil A Siddiqui, Li Zhang, Gabriel DeLeon, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
Pageof 70